Attendee search 

Senior Consultant at Nicholas Hall Consultancy. I am the Head the M&A and Licensing department as well as manage strategic consultancy projects (e.g. market entry, product launches, pricing, etc). I, along with my team have helped global pharma companies and private equity firms find suitable acquisition and licensing opportunities. Let's meet to discuss how Nicholas Hall Consultancy can help you. 

GeneriNobel is a privately owned pharmaceutical company, based in Germany, which outlicenses generic drugs (Rx) and OTC developments for the European market.

Key therapeutic areas are cardiovascular diseases, central nervous system and metabolism. GeneriNobel has a focus on dossier development, registration and outlicensing of generic / OTC drugs and represents the marketing authorization / dossier portfolio of its partner, the turkish multinational pharmaceutical company Nobel Ilaç (own R&D and manufacturing of APIs and finished products).

We offer:

* Out-licensing of generic / OTC drugs (dossiers) at an advanced stage of regulatory approval procedure, e. g. Rosuvastatin.

* Out-licensing of generic / OTC drugs (marketing authorisations / dossiers) with granted marketing authorisations in Germany and which are available for further registration procedures in Europe, e. g. Solifenacin, Rasagiline, Duloxetine, Aripiprazole, Memantine, Irbesartan and Irbesartan-HCTZ, Sildenafil, Escitalopram, Pantoprazole and Omeprazole.

We are interested in:

Marketing and Sales companies who are interested to in-license products of our Portfolio.

We are NOT interested in:

* regulatory service providers, IP service providers, legal advisors, APIs.

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. Since 2012, Helsinn has been coordinating clinical and regulatory activities in China from Beijing and in 2017 established an office in Shanghai to pursue commercial activities. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, and the U.S., as well as a product presence in approximately 190 countries globally.

Specialties: Business Development, Licensing and Market Research support, Alliance Management and Customer Relations to the Biotech, Medtech, Pharmaceutical and Life Sciences Industries, and Start-Up Coaching.

www.linkedin.com/in/simon-bennett-0390796

1.  Looking for co-investment opportunities under TPI's i2020 Accelerator scheme: early-stage, seed round, small molecule focus

2.  Looking for assets for licensing for clients, including: rare disease assets (except cell & gene therapy), CVD, pain management, respiratory, innovative technologies, 505(b)(2) products

3.  Meeting companies interested in state-of-the -art machine learning solutions for drug discovery

4.  Meeting companies interested in acquiring antibody libraries

5.  Meeting companies interested in acquiring a phase II ready asset in multiple myeloma

6.  Meeting companies interested in a range of market-ready nickel allergy products

Medis doo is the leading commercialization partner for innovative companies in the CSEE region. With 29 years of experience, we have proven our capabilities and reliability to many most admired pharmaceutical/biotech companies. We have the highest financial rating, 300+ employees and strong presence in hospital and retail.

Medis is looking for new cutting-edge medical solutions, to address unmet medical needs in the CSEE.

We will give you all the power you need to run your partnering, investment and funding activities backed up by our experienced valuation team, solid and proven valuation tool. Xplico Evaluator is an easy-to-use, flexible MS Excel-based valuation tool with integrated risk assessment and powerful analysis features for the life science industry.

Our Biotech package includes valuation tool, training and valuation support for a low fixed monthly fee. 

We will be able to support you with latest market and benchmark data, build and review business cases and step in if you are short of resources. 

We can evaluate your projects and/or company for a fixed competitive fee or support you during partnering negotiations.

Xplico was established in 2005 with the purpose of develop and market an easy-to-use and standardized tool for valuation of project and portfolio in the life science industry. Xplico is today the market leader in valuation supporting more than 75 life science companies in Europe and US on a day to day basis

Our team today has unique extensive experience in valuation, forecasting and project/portfolio management, as well as in-depth knowledge of business processes in the life science industry, information technology and financial systems.